Top Markets
Coin of the day
DICE Therapeutics, Inc. DICE Therapeutics, Inc.

DICE Therapeutics, Inc.

DICE
株式のランク #9048
DICE Therapeutics, Inc. is a biopharmaceutical firm focused on creating... DICE Therapeutics, Inc. is a biopharmaceutical firm focused on creating innovative oral drug candidates to address chronic immunological disorders and other medical conditions. The company leverages its proprietary DELSCAPE platform, engineered to identify highly selective oral small molecules that can modulate protein-protein interactions (PPIs) with efficacy comparable to conventional systemic biologics. Their flagship therapeutic asset is DC-806, an orally administered antagonist designed to inhibit interleukin-17, a pivotal pro-inflammatory signaling molecule widely recognized as a validated target across numerous immunology indications. Furthermore, DICE is advancing other oral treatment options, including therapies aimed at the α4β7 integrin for the management of inflammatory bowel diseases, and compounds targeting the αVβ1/αVβ6 integrin to treat idiopathic pulmonary fibrosis. Beyond these areas, the company also dedicates efforts to immuno-oncology, specifically developing antibody-based therapeutics. Established in 2013, DICE Therapeutics is headquartered in South San Francisco, California.
株価
$47.55
最終同期: 2023-08-18
時価総額
$1.10B
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 DICE Therapeutics, Inc. (DICE)

カテゴリー

DICE Therapeutics, Inc.(DICE)の利益
2026 時点の利益 TTM: 0
DICE Therapeutics, Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
DICE Therapeutics, Inc. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差
$5.27B -
US
$1.95B -
NL
$-4.02B -
AU
$-3.09B -
US
- -
CH